PATENT CLAIM ANALYSIS

Application Number: 15925148
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-11
Patent Classification: ["435", "325000"]

Abstract:
The invention provides an isolated, purified population of human cells comprising CD8 +  T cells with reduced Cbl-b activity. The invention provides uses of such cells in methods for inducing or enhancing an anti-tumor immune response in a subject. These methods comprise: (a) providing a cell population, from a subject or from another source, which comprises CD8 +  T cells, (b) reducing Cbl-b activity in the CD8 +  T-cells, (c) administering the cells of step (b) to the subject. The invention provides methods for making CD8 +  T cells that do not require stimulation through a co-receptor in order for the cell to become activated or proliferated in response to contact via its T cell receptor. Such methods are based upon reducing function of Cbl-b. The invention also provides methods for identifying agents which affect Cbl-b expression or activity.

Claim (Index 34):
The method of  claim 31 , wherein the population of cells which comprises CD8+ cells has been modified ex vivo to reduce Cbl-b activity.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 90.0
- Lexical Diversity: 2.01266
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15089016', '12441335', '12747326', '15458339', '14354562']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7000278540057467
- 35 USC 102 Novelty (BERT): 0.6288252908876862
- Combined Prediction Score: 0.6929075976939407
- Mean Citation Score: 518.409566
- Max Citation Score: 761.80585
- Similarity Product: 521.3031570029617

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test